03.17.25 -- Managing Risk When Developing Combination Products

Everything from glass or plastic bottles to the ink used in labels can leach unwanted contaminants. The first challenge chemists address is to narrow the focus on the most likely suspects.

Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and adherence while expanding the therapeutic market.

Examine the case study and learn how formulating an orally disintegrating tablet (ODT) created a convenient dosage form with a shorter T_max for the treatment of acute migraine.

See how PBPK models combined with custom and off-the-shelf in vitro tools and solubility enhancement expertise can reduce the need for drug product reformulation or repeated preclinical or clinical studies.

Uncover the importance of scalability and flexibility in early-stage manufacturing strategy and how that decision impacts financial outcomes for a development program.

Learn how sterile injectable devices are providing safer and more convenient self-injection delivery, leading to positive patient experiences, better therapy adherence, and improved outcomes.